Results 51 to 60 of about 691 (136)

Association between chronic diseases and severe periodontal disease progression: A retrospective cohort study in a city of Japan

Journal of General and Family Medicine, Volume 26, Issue 1, Page 54-64, January 2025.
This manuscript is a study demonstrating the association between the progression of severe periodontal diseases and chronic diseases commonly addressed in primary care. We used claims data and defined the outcome as the “progression of severe periodontitis” and followed patients for 4 years.
Sayaka Nin, Yu Sun, Takami Maeno, Chihiro Nishiura, Kento Taira, Kenji Fujimoto, Jun Hamano, Sachiko Ozone, Tetsuhiro Maeno   +8 more
wiley   +1 more source

Formulations of Amlodipine: A Review

Journal of Pharmaceutics, Volume 2016, Issue 1, 2016., 2016
Amlodipine (AD) is a calcium channel blocker that is mainly used in the treatment of hypertension and angina. However, latest findings have revealed that its efficacy is not only limited to the treatment of cardiovascular diseases as it has shown to possess antioxidant activity and plays an important role in apoptosis. Therefore, it is also employed in
Muhammad Ali Sheraz, Syed Furqan Ahsan, Marium Fatima Khan, Sofia Ahmed, Iqbal Ahmad, Francisco Javier Flores-Murrieta   +5 more
wiley   +1 more source

Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT)

The Journal of Clinical Hypertension, Volume 27, Issue 1, January 2025.
ABSTRACT Angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) are commonly prescribed as first‐ and second‐line treatments for older Japanese patients with hypertension. However, due to age‐related decline in renin activity, the effectiveness of ARBs may decrease.
Kazuomi Kario, Tomohiro Katsuya, Tatsuo Shimosawa, Takashi Taguchi, Ayumi Tanabe, Mitsuru Ohishi, the ESCORT‐HT investigators   +6 more
wiley   +1 more source

Modern approaches to the treatment and long-term management of arterial hypertension in clinical practice. Pharmacological and clinical characteristics of angiotensin II receptor blockers: focus on azilsartan medoxomil. Part I

КардиоСоматика, 2015
This article deals withthe overview of the pharmacological characteristics of one class of antihypertensive drugs - angiotensin II receptor antagonists (ARA II) and new member of this class - azilsartan medoxomil (Edarbi®).We have analyzed the ...
M. G Bubnova
doaj  

BRASH syndrome: а clinical case

Рациональная фармакотерапия в кардиологии
The article describes a clinical case of BRASH syndrome in patient M., born in 1938, suffering from hypertension and diabetes mellitus. The patient took bisoprolol, eplerenone, azilsartan medoxomil, lercanidipine hydrochloride daily.
D. D. Shalaeva, K. G. Pereverzeva, O. A. Fomina, S. S. Yakushin   +3 more
doaj   +1 more source

Comparative analysis of antihypertensive effects of chlorthalidone and indapamide-retard in combination with azilsartan medoxomil in patients with arterial hypertension

Российский кардиологический журнал, 2019
Achievement of target blood pressure (BP) is one of the key strategies of primary prevention of cardiovascular complications in patients with arterial hypertension (AH). Aim.
Zh. D. Kobalava, V. V. Kulakov, L. A. Goreva, S. V. Villevalde   +3 more
doaj   +1 more source

Coadministration of Cardiomagnyl with Edarbi/Edarbi Clo in comparison with enteric-coated acetylsalicylic acid and renin-angiotensin-aldosterone system blockers in patients with hypertension and atherosclerotic cardiovascular diseases in the Russian Federation. Results of the CARAT study

Российский кардиологический журнал
Aim. To compare clinical outcomes in patients with hypertension and atherosclerotic cardiovascular diseases (CVDs) prescribed a combination of buffered acetylsalicylic acid (BA) (Cardiomagnyl®) + Azilsartan/Azilsartan+chlorthalidone (Edarbi/Edarbi Clo ...
F. T. Ageev, M. D. Smirnova, A. N. Kaftanov, D. V. Gavrilov   +3 more
doaj   +1 more source

Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations

Research Reports in Clinical Cardiology, 2013
Jocelyn D Jones,1 Sylvia H Jackson,1 Charlie Colquitt21College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Jacksonville, FL, USA; 2College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tampa, FL ...
Jones JD, Jackson SH, Colquitt C
doaj  

Critical evaluation of the efficacy and tolerability of azilsartan

Vascular Health and Risk Management, 2012
Alberto R De Caterina1,2, Andrew R Harper2,3, Florim Cuculi21Istituto Scienze della Vita, Scuola Superiore Sant'Anna, Pisa, Italy; 2Oxford University Hospitals, Oxford; 3Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne ...
Cuculi F, Harper AR, De Caterina AR
doaj  

Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension

International Journal of Medical and Dental Sciences, 2018
Hypertension is an important risk factor for cardiovascular and renal disease. It’s early detection and control is critically important as it is an important attributable cause of stroke, coronary artery disease, heart failure, atrial fibrillation and ESRD. Recent data indicates increasing prevalence of hypertension amongst various populations.
Megha Sood, Jagminder Kaur Bajaj, Jagminder Kaur Bajaj   +2 more
openaire   +2 more sources